Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Tirzepatide stories

Nov 9, 2026

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.

Nov 9, 2026·8 sources
00
Oct 28, 2026

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources
00
Sep 30, 2026

Eli Lilly's amylin-Zepbound combination shows record 23% weight loss in diabetes trial

Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.

Sep 30, 2026·6 sources
00
May 1, 2026

FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding List

FDA announced plans to exclude semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.

May 1, 2026·1 source
00
Apr 18, 2026

Weight Loss Medications Lead to Notable Muscle Loss Alongside Fat Loss

UNC School of Medicine study finds incretin-based medications including semaglutide and tirzepatide cause significant muscle loss in addition to fat reduction, raising concerns about long-term metabolic effects.

Apr 18, 2026·1 source
00
Apr 10, 2026

AI Analysis of 400,000 Reddit Posts Identifies Overlooked GLP-1 Drug Side Effects

University of Pennsylvania researchers used AI to analyze over 400,000 Reddit posts to identify patient-reported symptoms associated with semaglutide and tirzepatide that may not be captured in clinical trials.

Apr 10, 2026·1 source
00

Top claims

  • ▪The FDA required all GLP-1 drug manufacturers to add a nonarteritic anterior ischemic optic neuropathy safety warning to drug labels
  • ▪Cases of nonarteritic anterior ischemic optic neuropathy have been reported across all currently marketed GLP-1 medications, including semaglutide and tirzepatide products
  • ▪Nonarteritic anterior ischemic optic neuropathy is a rare eye condition caused by reduced blood flow to the optic nerve that can lead to sudden, permanent vision loss or blindness

Topics

Drug labeling & regulationDrug Policy, Pricing & ApprovalDrug safety & pharmacovigilanceGLP-1 medicationsEli LillyDrug safetyPost-market surveillanceGLP-1 receptor agonistsFDA regulationZepboundNovo NordiskGLP-1 drug side effectsWeight managementBlood sugar & insulinWeight loss drugsRetatrutideClinical trialsDrug developmentMetabolic healthGLP-1 / Weight-Loss MedicationsDrug Approval and Clinical TrialsLifestyle, Wellness and NutritionWeight loss medications & GLP-1 drugsHealthcare PolicyEnvironmental and Occupational HealthEnvironmental exposures & toxicologyDiet & nutritionHealthAI data analysisAI safety & social impactAI privacy & surveillanceAI research & benchmarksAI

Related entities

OzempicSemaglutideUnited StatesLiraglutide